Results 101 to 110 of about 2,891 (162)

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Spriano F, Cascione L, Tarantelli C, Sartori G, Arribas AJ, Velasova A, Napoli S, Havranek O, Toretsky JA, Bertoni F.   +9 more
europepmc   +1 more source

Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review. [PDF]

Cancer Control
Al-Mashdali AF, Ghasoub R, Hwafdeh S, Yassin MA.   +3 more
europepmc   +1 more source

Identification of biomarkers in myocardial hypertrophy and fibrosis via integrated transcriptomic and phosphoproteomic profiling. [PDF]

Sci Rep
Luo K, Ma Y, Zhang Y, Zi Y, Guo G, Chen X, Feng W, Jing Q, Li L, Han S, Zheng B.   +10 more
europepmc   +1 more source

Inhibition of XPO1 by selinexor enhances terminal erythroid maturation through modulation of HSP70 trafficking in severe β0-thalassemia/HbE. [PDF]

PLoS One
Khamphikham P, Tantiworawit A, Anuchapreeda S.   +2 more
europepmc   +1 more source

Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. [PDF]

Blood Adv
Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J, Fan L, Chen L.   +7 more
europepmc   +1 more source

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how? [PDF]

Transl Lung Cancer Res
Nagasaka M, Khan HY, Luo F, Al-Hallak MN, Saif MW, Mohammad RM, Azmi AS.   +6 more
europepmc   +1 more source

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. [PDF]

Am J Hematol
Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, Fedorov K, Kishtagari A, Mohan SR, Ayers GD, Byrne MT, Savona MR.   +11 more
europepmc   +1 more source

In-silico identification of genetic variants associated with chronic lymphocytic leukemia for diagnostic and therapeutic applications. [PDF]

Sci Rep
Islam MS, Mollah MMH, Ahsan MA, Ali M, Al Noman M, Ahmed MF, Latif MA, Pal NK, Faysal MF, Mollah MNH.   +9 more
europepmc   +1 more source

Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer. [PDF]

J Exp Clin Cancer Res
Altman JE, Valentine A, Dashti-Gibson N, Zboril EK, Boyd DC, Myrick RK, Olex AL, Dozmorov MG, Harrell JC.   +8 more
europepmc   +1 more source

Cortical organoid-derived models of the melanoma brain metastatic niche enable prioritization of cancer-targeting drugs. [PDF]

Cell Rep Methods
Krieg K, Materna-Reichelt S, Naber T, Rachad FZ, Kauven P, Weller A, Haferkamp U, Wittich A, Zaliani A, Woo MS, Walkenhorst M, Siegmund M, Harberts J, Zierold R, Blick R, Conze C, Muschong P, Miltner D, Friese MA, Mezler M, Siegmund H, Evert K, Krasemann S, Gužvić NS, Klein CA, Werner-Klein M, Wegener J, Pless O.   +27 more
europepmc   +1 more source